

SUPPLEMENTARY ONLINE DATA

Identification of novel small molecules that elevate Klotho expression

Gwendalyn D. KING^{*1}, CiDi CHEN^{*}, Mickey M. HUANG[†], Ella ZELDICH^{*}, Patricia L. BRAZEE^{*}, Eli R. SCHUMAN[†], Maxime ROBIN[‡], Gregory D. CUNY[†], Marcie A. GLICKSMAN[†] and Carmela R. ABRAHAM^{*2}

^{*}Boston University School of Medicine, Department of Biochemistry, 72 East Concord Street K304, Boston, MA 02118, U.S.A., [†]Laboratory for Drug Discovery in Neurodegeneration, Brigham & Women's Hospital and Harvard Medical School, 65 Landsdowne Street, 4th Floor, Cambridge, MA 02139, U.S.A., and [‡]Aix-Marseille Université Laboratoire Chimie Provence LCP-UMR CNRS 6264, Centre Saint Jérôme, Service 552, 13397 Marseille Cedex 20, France




Figure S1 Compounds that do not activate the *KL* promoter

Compounds reported to elevate levels of KL were tested to determine whether they activated *KL* transcription in our system. A plasmid containing 1800 bp of the *KL* promoter driving luciferase transcription was transiently transfected with a constitutively expressing *Renilla* reporter plasmid. After 24 h, compounds were added to fresh medium overlaying the cells. Luciferase output was determined 24 h later. Results are means \pm S.E.M. ($n = 3$) expressed as fold change compared with the no treatment control (1800).

Received 23 November 2010/20 September 2011; accepted 22 September 2011
 Published as BJ Immediate Publication 22 September 2011, doi:10.1042/BJ20101909

¹ Present address: Department of Neurobiology, University of Alabama at Birmingham, Shelby 911, 1825 University Boulevard, Birmingham, AL 35294-2182, U.S.A.

² To whom correspondence should be addressed (email cabraham@bu.edu).